Light Sciences Oncology Meets a Major Milestone in Aptocine Development With Target Enrollment in Phase 3 MCRC Trial

Friday, February 26, 2010 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

Company Also Anticipates Phase 3 Results for Aptocine in HCC, Progress in Other Trials, and More Immune-Response Studies

Contacts

Llew Keltner, M.D., Ph.D.

President & CEO

425-957-8940

[email protected]

Robert M. Littauer

Vice President, Chief Financial Officer & Treasurer

425-957-8946

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store